176 related articles for article (PubMed ID: 2248164)
21. Biodegradable microspheres containing adriamycin in the treatment of proliferative vitreoretinopathy.
Moritera T; Ogura Y; Yoshimura N; Honda Y; Wada R; Hyon SH; Ikada Y
Invest Ophthalmol Vis Sci; 1992 Oct; 33(11):3125-30. PubMed ID: 1399416
[TBL] [Abstract][Full Text] [Related]
22. A refined experimental model for proliferative vitreoretinopathy.
Chandler DB; Quansah FA; Hida T; Machemer R
Graefes Arch Clin Exp Ophthalmol; 1986; 224(1):86-91. PubMed ID: 2417916
[TBL] [Abstract][Full Text] [Related]
23. HGF regulation of RPE proliferation in an IL-1beta/retinal hole-induced rabbit model of PVR.
Liou GI; Pakalnis VA; Matragoon S; Samuel S; Behzadian MA; Baker J; Khalil IE; Roon P; Caldwell RB; Hunt RC; Marcus DM
Mol Vis; 2002 Dec; 8():494-501. PubMed ID: 12500176
[TBL] [Abstract][Full Text] [Related]
24. Early vitreous changes in experimental proliferative vitreoretinopathy.
Miglior S; Kain HL; Libondi T; González RG; Barnett P; Krauss JM; Cheng HM
Arch Ophthalmol; 1986 Nov; 104(11):1681-4. PubMed ID: 3778288
[TBL] [Abstract][Full Text] [Related]
25. Effect of 3,3'-iminodipropionitrile on experimental intravitreal proliferation in albino rabbits.
Akiyama K
Jpn J Ophthalmol; 1990; 34(4):401-8. PubMed ID: 2082060
[TBL] [Abstract][Full Text] [Related]
26. Measurement of cellular proliferation within the vitreous during experimental proliferative vitreoretinopathy.
Yang CM; Olsen KR; Hernandez E; Cousins SW
Graefes Arch Clin Exp Ophthalmol; 1992; 230(1):66-71. PubMed ID: 1547971
[TBL] [Abstract][Full Text] [Related]
27. Pharmacological therapy for proliferative vitreoretinopathy.
Radtke ND; Weinsieder AD; Ballou RJ
Graefes Arch Clin Exp Ophthalmol; 1986; 224(3):230-3. PubMed ID: 3710177
[TBL] [Abstract][Full Text] [Related]
28. Fluorouracil therapy for proliferative vitreoretinopathy after vitrectomy.
Stern WH; Lewis GP; Erickson PA; Guerin CJ; Anderson DH; Fisher SK; O'Donnell JJ
Am J Ophthalmol; 1983 Jul; 96(1):33-42. PubMed ID: 6869478
[TBL] [Abstract][Full Text] [Related]
29. Effect of 2'-benzoyl-oxycinnamaldehyde on RPE cells in vitro and in an experimental proliferative vitreoretinopathy model.
Lee JJ; Park JK; Kim YT; Kwon BM; Kang SG; Yoo YD; Yu YS; Chung H
Invest Ophthalmol Vis Sci; 2002 Sep; 43(9):3117-24. PubMed ID: 12202537
[TBL] [Abstract][Full Text] [Related]
30. [The significance of fibroblasts in experimental modeling of proliferative vitreoretinopathy].
Khoroshilova-Maslova IP; Leparskaya NL; Vorotelyak EA; Vasiliev AV
Vestn Oftalmol; 2017; 133(5):4-10. PubMed ID: 29165406
[TBL] [Abstract][Full Text] [Related]
31. Vitreous aspirates from patients with proliferative vitreoretinopathy stimulate retinal pigment epithelial cell migration.
Campochiaro PA; Jerdan JA; Glaser BM; Cardin A; Michels RG
Arch Ophthalmol; 1985 Sep; 103(9):1403-5. PubMed ID: 4038135
[TBL] [Abstract][Full Text] [Related]
32. Retinoic acid in silicone and silicone-fluorosilicone copolymer oils in a rabbit model of proliferative vitreoretinopathy.
Nakagawa M; Refojo MF; Marin JF; Doi M; Tolentino FI
Invest Ophthalmol Vis Sci; 1995 Nov; 36(12):2388-95. PubMed ID: 7591628
[TBL] [Abstract][Full Text] [Related]
33. Intravitreal sustained release corticosteroid-5-fluoruracil conjugate in the treatment of experimental proliferative vitreoretinopathy.
Berger AS; Cheng CK; Pearson PA; Ashton P; Crooks PA; Cynkowski T; Cynkowska G; Jaffe GJ
Invest Ophthalmol Vis Sci; 1996 Oct; 37(11):2318-25. PubMed ID: 8843916
[TBL] [Abstract][Full Text] [Related]
34. The effect of triamcinolone acetonide on a refined experimental model of proliferative vitreoretinopathy.
Chandler DB; Rozakis G; de Juan E; Machemer R
Am J Ophthalmol; 1985 Jun; 99(6):686-90. PubMed ID: 2409802
[TBL] [Abstract][Full Text] [Related]
35. Antiproliferative drugs in the treatment of experimental proliferative vitreoretinopathy.
Kirmani M; Santana M; Sorgente N; Wiedemann P; Ryan SJ
Retina; 1983; 3(4):269-72. PubMed ID: 6201971
[TBL] [Abstract][Full Text] [Related]
36. Liposome-encapsulated 5-fluorouracil in the treatment of proliferative vitreoretinopathy.
Joondeph BC; Peyman GA; Khoobehi B; Yue BY
Ophthalmic Surg; 1988 Apr; 19(4):252-6. PubMed ID: 3362494
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of radiation therapy for experimental proliferative vitreoretinopathy in rabbits.
Kuriyama S; Ohuchi T; Yoshimura N; Honda Y; Hiraoka M; Abe M
Graefes Arch Clin Exp Ophthalmol; 1990; 228(6):552-5. PubMed ID: 2265771
[TBL] [Abstract][Full Text] [Related]
38. [The role of specific ROCK inhibitor in the prevention of experimental PVR in rabbits].
Zheng YP; Sun NX; Xiong QC; Quan YL; Wang F
Zhonghua Yan Ke Za Zhi; 2005 Dec; 41(12):1112-8. PubMed ID: 16409766
[TBL] [Abstract][Full Text] [Related]
39. Expression of growth factor mRNA in rabbit PVR model systems.
Planck SR; Andresevic J; Chen JC; Holmes DL; Rodden W; Westra I; Wu SC; Huang XN; Kay G; Wilson DJ
Curr Eye Res; 1992 Nov; 11(11):1031-9. PubMed ID: 1282856
[TBL] [Abstract][Full Text] [Related]
40. Proliferative vitreoretinopathy and chemotherapeutic agents.
Peyman GA; Schulman J
Surv Ophthalmol; 1985; 29(6):434-42. PubMed ID: 3892742
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
